Orchid Pharma Limited — Investor Meet, 11-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Orchid Pharma's Q3 FY26 saw sales dip 5% YoY to 207 Cr. EBITDA plunged 65% to 13 Cr, with margins shrinking significantly from 17% to 6%. The company posted a net loss of 6 Cr for the quarter, a sharp reversal from 24 Cr profit last year. For 9M FY26, sales were down 16% to 574 Cr, and profit fell from 78 Cr to 15 Cr. Gross margins also contracted. The numbers reflect a tough operating environment, showing notable pressure on profitability this quarter and year-to-date.